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Abstract Background: Checkpoint inhibitors (CIs) are highly effective but can induce severe
immune-related adverse events (irAEs), which cannot be predicted. We investigated whether
human leukocyte antigen (HLA) genes predispose to developing of irAEs during therapy
and thus hold a predictive role.
Methods: We established a prospective observational single-centre study and collected data
from patients with either metastatic nonesmall cell lung cancer (NSCLC) or metastatic mel-
anoma, who were treated with antiePD-1 (programmed cell death receptor 1), anti-CTLA4
(cytotoxic T-lymphocyteeassociated protein 4) or both CIs combined. Data include irAEs
and ranges from 15th July 2016 until 10th May 2018. In addition, we performed HLA typing
via next generation sequencing.
Results: We enrolled 102 patients (median [range] age, 68 [62e74] years) with metastatic can-
cer in our study who received CI therapy. Of these patients, 59 (58%) developed one or more
irAEs, among which pruritus (n Z 32 (54%)) and rash (n Z 24 (41%)) had the highest rates.
We did not find evidence for a single HLA gene being associated with all irAEs (all P > .05).
When assessing each irAE individually, we found a significant association between HLA-
DRB1*11:01 and pruritus (OR Z 4.53, X21,95 Z 9.45, P < .01) as well as a nominally
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significant additive association between HLA-DQB1*03:01 and colitis (OR Z 3.94,
X21,95 Z 5.67, P Z .017).
Conclusions: The presence of two HLA alleles that are known to predispose to autoimmune
diseases were associated with the development of pruritus or colitis during therapy, suggesting
a genetic aetiology of irAEs. Larger genome-wide association studies should be performed to
confirm our findings.
ª 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Checkpoint inhibitors (CIs) have significantly prolonged
overall survival in metastatic cancer patients and have
ushered a new treatment era in clinical oncology [1,2].
However, all CIs entail immune-mediated adverse
events (irAEs), also referred to as toxicities, that can
affect all organs and range from a mild skin rash
managed by topical corticosteroids to fulminant colitis
or myocarditis, requiring hospitalisation [3e7].
Although the exact mechanisms remain unclear, it is
suspected that irAEs are caused by interference of CIs
with tolerance mechanisms mediated by cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) [8,9] and the
programmed cell death protein (PD-1) [10,11].
Currently, there are no markers before therapy to pre-
dict if an irAE will develop during treatment, except
patients suffering from preexisting autoimmune disease,
who may experience flares of their respective condition
during therapy [12,13]. Severe irAEs require pausing CI
therapy and are treated with immunosuppressive drugs
[5,14e16].
Interestingly, some irAEs resemble well-characterised
autoimmune diseases with defined human leukocyte
antigen (HLA) risk alleles. Examples are generalised
pruritus and atopic dermatitis [17,18], colitis and in-
flammatory bowel diseases [19], thyroiditis and Grave’s
disease [20,21] as well as arthritis and rheumatoid
arthritis [22].
The aim of this study was to explore whether HLA
genes known to mediate susceptibility for autoimmunity
are also associated with development of irAEs in met-
astatic cancer patients during CI therapy.
2. Materials and methods
2.1. Study population
We established a monocentric prospective observational
study and enrolled patients with metastatic non-small
cell lung cancer (NSCLC) or metastatic melanoma, who
received CI treatment with either anti-PD-1, anti-PD-
ligand-1 (PD-L1), anti-CTLA4 or a combination anti-
PD-1 and anti-CTLA4. The end of the follow-up period
was 10th May 2018. The study was approved by the
local ethics committee (Project ID 2016e009918) and
was conducted accordingly.
All participants were from Eastern Switzerland and
of European ancestry. Patients were at least 18 years of
age and presented with either NSCLC or metastatic
melanoma. Treatment consisted of CIs including ipili-
mumab (anti-CTLA4), pembrolizumab (antiePD-1),
nivolumab (antiePD-1) or atezolizumab (anti-PD-L1)
for at least one cycle. IrAE development was monitored
from therapy start and was included into this study if
onset was before 11th May 2018 (end of data collection).
Monitoring was conducted by oncologists and cat-
egorised as follows, with respect to CTCAE V4.03: rash,
Table 1
Characteristics of patients with NSCLC or melanoma receiving
checkpoint inhibitor therapy.
Characteristic Patient count (N Z 102)
N (%)
irAEa 59 (58)
No irAE 43 (42)
Age (median [IQRb]) 68 (62e74)
Sex
Male 52 (51)
Female 50 (49)
Cancer type
NSCLC 66 (65)
Melanoma 36 (35)
Treatment
PD-(L)1c inhibitor 92 (90)
Nivolumab 38 (37)
Pembrolizumab 47 (46)
Atezolizumab 7 (7)
CTLA-4d inhibitor 10 (10)
Ipilimumab alone 4 (4)
Ipilimumab with nivolumab 6 (6)
Smoking (only NSCLCe)
Yes 60 (59)
Pack years (median [IQR]) 40 (30e60)
No 5 (5)
Unknown 1 (1)
Sunburns (only melanoma)
Never 1 (3)
Rare 32 (91)
Frequent 2 (6)
Unknown 1 (3)
airAE, immune-related adverse event; bIQR, interquartile range;
cPD(L)-1, programmed cell death protein (ligand)e1; dCTLA4, cyto-
toxic T-lymphocyteeassociated protein 4; eNSCLC, nonesmall cell
lung cancer.
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generalised pruritus, vitiligo, colitis, pneumonitis, hep-
atitis, thyroiditis, hypophysitis, arthritis and others
(asthenia, fatigue, nephritis and Guillain-Barre´ syn-
drome). Each irAE was documented via database tech-
nology (SecuTrial, version 5.3.0.10). If toxicity was
equal to or exceeded common terminology criteria for
adverse events (CTCAE) grade 3, it was independently
verified by a physician trained in the respective medical
speciality. High-resolution HLA haplotyping was per-
formed using next generation sequencing (ProImmune
Ltd., Oxford, UK and Histogenetics LLC, New York,
USA). With this technology, complete HLA class I (A,
B, C) and class II (DRB1, DPB1 and DQB1) genes were
sequenced, resulting in second field (four digit) allele-
level HLA types with no degeneracy.
2.2. Statistical analysis
Logistic regression models used for the main association
analyses included several covariates that might poten-
tially confound the risk for irAEs: patient age and sex,
cancer type (NSCLC or melanoma) and specific CI used
in therapy. When testing association of an entire HLA
locus, we included all common variants of that locus as
separate terms in the model. When testing for association
of specific HLA variants, we included only that variant
in the model. For the association test, we only analysed
common variants (allele frequency >.1 in our cohort)
and only included variants from the four HLA loci most
frequently associated with autoimmune diseases: HLA-B
(N Z 2 alleles), HLA-C (N Z 3), HLA-DRB1 (N Z 4)
and HLA-DQB1 (N Z 4) [23]. We controlled for the
false discovery rate (FDR) using a Bonferroni-corrected
significance threshold (PZ .05/13Z .0038). For the Cox
proportional hazard regression models, we used the
coxph function of the survival package in R. All analyses
were conducted in R version 3.4.2.
3. Results
3.1. Study population
To identify HLA associations with irAEs, we enrolled a
total of 102 patients (median [interquartile range] age,
68 [62e74] years) with metastatic cancer in our study
who received CI therapy. Sixty-six (65%) had been
Fig. 1. Immune-mediated adverse events (irAEs) in cancer patients. Number and frequency of irAEs in nonesmall cell lung cancer and
melanoma patients treated with checkpoint inhibitors. (A) Distribution of the number of irAEs per patient (0e5, NZ 102). (B) A bar plot
illustrating the numbers of patients affected with each irAE (N Z 59).
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diagnosed with stage IV NSCLC, and 36 (35%), with
stage IV melanoma. Ninety-two (90%) patients were
treated with antiePD-1 (nivolumab or pembrolizumab)
or anti-PD-L1 (atezolizumab) treatment alone. Six (6%)
patients had dual treatment with anti-CTLA-4 (ipili-
mumab) and antiePD-1 (nivolumab), and four (4%)
patients received anti-CTLA-4 therapy (ipilimumab)
only. The clinical characteristics are summarised in
Table 1. Of these patients, 59 (58%) developed one or
more irAEs (Fig. 1).
3.2. Associating irAEs with HLA
First, we tested whether a common genetic variation at
the four investigated HLA loci (HLA-B, -C, -DRB1,
-DQB1) was associated with the risk of developing any
irAE, regardless of the affected organ. We did not find
evidence for a general association between HLA and
developing any irAE during CI therapy, regardless of
the affected organ (all P > .05). This was expected
because, as with irAEs, autoimmune disorders are
organ-specific, and each is individually associated with
certain HLA variants and loci. Next, we focused on the
group of skin-related toxicities only (pruritus and rash).
Our analysis revealed no effect of HLA class I genes
(P > .05). However, the risk to develop one or more
skin-related irAE was nominally associated with com-
mon variation in HLA-DRB1 (X24,92Z 15.21, PZ .004)
and HLA-DQB1 (X24,92Z 13.35, PZ .01). Encouraged
by these results, we proceeded to analyse pruritus and
Fig. 2. Association between HLA variants and pruritus. (A) Allele frequencies of 13 common HLA variants among cancer patients treated
with checkpoint inhibitors. They are shown separately for patients without (light blue bars) and with (dark blue bars) immune-mediated
pruritus. Only the association of HLA-DRB1*11:01 and pruritus is significant (ORZ 4.53, X21,95Z 9.45, **PZ .0021, NZ 102). HLA-
DQB1*03:01 is commonly associated with HLA-DRB1*11:01 and, by itself, shows no significant association with pruritus. (B) Patients
carrying the HLA variant DRB1*11:01 are more likely to exhibit pruritus than patients with other HLA haplotypes (N Z 102). (C)
Concurringly, patients without pruritus are very likely not to carry HLA-DRB1*11:01 (interrupted line), whereas only very few carriers of
this variant remain free of pruritus (full line). KaplaneMeier survival curves with 95% log hazard confidence intervals (shaded areas). For
visualisation, a patient with follow-up time >2000 days was excluded in this plot (N Z 101). OR, odds ratio. (For interpretation of the
references to color/colour in this figure legend, the reader is referred to the Web version of this article.)
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rash separately to focus on their individual associations
with specific variants in those two genes. With this
approach, we found a significant association between
HLA-DRB1*11:01 and pruritus that exceeded the
study-wide FDR-corrected significance threshold
(OR Z 4.53, X21,95 Z 9.45, P Z 0.002, Fig. 2A). This
association became even stronger when testing for the
presence/absence of the variant, rather than assuming an
additive risk model (X21,95 Z 10.47, P Z 0.0012). This
might indicate a slight dominance effect of this variant
on pruritus risk. The association is supported by liter-
ature, because an association between atopic dermatitis
and DRB1*11:01 has been reported. During our anal-
ysis of the association between the presence of HLA-
DRB1*11:01 and pruritus, we noticed that in our
cohort HLA-DRB1*11:01 always co-occurs with the
variant HLA-DQB1*03:01, indicating genetic linkage
between HLA-DRB1 and HLA-DQB1. Such tightly
linked haplotypes in the HLA region are a common and
well-described phenomenon [24]. However, HLA-
DQB1*03:01 co-occurred with other HLA-DRB1 vari-
ants as well, which enabled us to additionally control for
a possible effect of HLA-DQB1 variation. Reassuringly,
the association of HLA-DRB1*11:01 remained nomi-
nally significant after conditioning on the presence of
common variants at the HLA-DQB1 locus (X21,91Z 5.1,
P Z .024). Investigating the proportional hazard of
developing pruritus with and without HLA-
DRB1*11:01 revealed that the effect of this variant
was even stronger than we initially assumed (propor-
tional hazard: 5.39, P < .001; Fig. 2B and C). Carriers of
this variant also presented earlier with pruritus than
those without the variant. Furthermore, we find a
possible trend for a protective association between
HLA-DRB1*01:01 and skin rash (ORZ .26 PZ .054).
Among the noneskin-related irAEs, colitis revealed a
nominally significant additive association with the HLA
class II variant HLA-DQB1*03:01 (OR Z 3.94,
X21,95 Z 5.67, P Z .017, see Fig. 3). Although low-to
medium-grade pruritus can be conveniently treated with
Fig. 3. Association between HLA variants and colitis. Allele frequencies of 13 common HLA variants among cancer patients treated with
checkpoint inhibitors (NZ 102). Orange bars show patients without immune-mediated colitis (NZ 93), whereas red bars depict patients
with colitis (N Z 9). Despite the small sample size of 9 patients with colitis, it revealed a nominally significant additive association, with
the HLA class II variant HLA-DQB1*03:01 (ORZ 3.94, X21,95Z 5.67, *PZ .017). OR, odds ratio. (For interpretation of the references
to color/colour in this figure legend, the reader is referred to the Web version of this article).
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topical corticosteroids, colitis presents a major clinical
challenge and a medical emergency, as it can lead to
colon perforation and death [25]. In addition, HLA-
DQB1*03:01 has been strongly linked to inflammatory
bowel diseases [19] further supporting its proposed link
with irAE colitis and linking HLA and irAEs in general.
All identified effects were independent of sex or age.
Other irAEs did not show any evidence for association
with specific HLA variants, potentially owing to the
limited case numbers in our cohort (all n  10).
4. Discussion
Our study reveals a previously unrecognised link be-
tween HLA alleles that are associated with autoimmune
diseases and the risk of developing organ-specific irAEs
during CI therapy. The findings are supported by the
following: (1) we demonstrate a statistically significant
association between developing pruritus and HLA-
DRB1*11:01; (2) we identified a nominally significant
association between HLA-DQB1*03:01 and colitis; (3)
previous reports that patients with autoimmune dis-
eases can exhibit flare-ups of their autoimmune disease
during CI therapy. The fact that we had a fairly limited
sample size for a genetic association study (NZ 102) at
our disposal further highlights the significance of the
found associations. Even though the discovery of an
association between HLA risk alleles and developing
irAEs may aid in risk calculations, some limitations
need to be addressed. First, we examined a cohort of
rather limited size (N Z 102). Second, irAEs during
checkpoint inhibition may appear at any given time,
sometimes after months, which may constitute a bias in
the time frame of data collection [4]. The increasing use
of CI therapies will allow recruiting a much larger
cohort over longer time that could eventually facilitate
a broader genetic investigation of these associations to
provide a better understanding of the HLA-associated
disease dynamics.
5. Conclusion
Our data suggest that a genetic HLA-mediated predis-
position for autoimmune diseases may lead to the
development of irAEs once the adaptive immune system
loses its tolerance against self-antigens through treat-
ment with CIs. Currently, severe irAEs lead to therapy
interruption and are treated with systemic immunosup-
pression, which may counteract the desired therapy ef-
fect. Identifying patients at risk for developing irAEs
prompts symptom monitoring and early interdisci-
plinary management among medical subspecialities. Our
results may contribute to the development of a screening
tool that is able to single out patients at risk for devel-
oping potentially high grade irAEs before CI therapy.
Such a tool would allow physicians to differentiate
between low- and high-risk patients with direct impli-
cations on patient monitoring and care.
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